(Total Views: 509)
Posted On: 11/06/2020 11:17:49 AM
Post# of 155689
HGEN, company is still blinded from interim data?
From Seeking Alpha article today:
Lenzilumab had a clinically meaningful impact on patient recovery, with an estimated 37% more recoveries observed in the lenzilumab arm (HR of 1.37) vs. current standard of care (SoC).
And that one little comment, drove their stock up so far, 9% today!
We were not given that "positive" statistic on our 195 s/c interim analysis???
That specific stat for us, was probably nearer to 70% ......
What's going on in this goofy world?
From Seeking Alpha article today:
Lenzilumab had a clinically meaningful impact on patient recovery, with an estimated 37% more recoveries observed in the lenzilumab arm (HR of 1.37) vs. current standard of care (SoC).
And that one little comment, drove their stock up so far, 9% today!
We were not given that "positive" statistic on our 195 s/c interim analysis???
That specific stat for us, was probably nearer to 70% ......
What's going on in this goofy world?
(1)
(0)
